Home › Job titles › Senior Manager, Biostatistics
Senior Manager, Biostatistics: H-1B salaries
67 labor condition applications used the job title Senior Manager, Biostatistics. Median offered base salary $159,650; middle half $149,458–$169,492.
Applications (LCAs)67
Median offered salary$159,650
Middle half of salaries$149,458–$169,492
10th–90th percentile$138,317–$181,668
Employers
| Employer | LCAs | Median salary |
|---|---|---|
| Bristol-Myers Squibb Company | 48 | $158,376 |
| Regeneron Pharmaceuticals, Inc. | 6 | $187,620 |
| Gilead Sciences, Inc. | 4 | $146,858 |
| Celgene Corporation | 2 | $138,945 |
| ModernaTX, Inc. | 1 | $185,000 |
| AbbVie Inc. | 1 | $164,000 |
| Kite Pharma Inc. | 1 | $118,664 |
| BeOne Medicines USA, Inc. | 1 | $172,848 |
| Genmab US, Inc. | 1 | $175,781 |
| Revolution Medicines, Inc. | 1 | $190,000 |
| Amgen Inc. | 1 | $175,950 |
By wage level
| Wage level | Median salary |
|---|---|
| Level II (qualified) | $148,218 |
| Level III (experienced) | $159,556 |
| Level IV (fully competent) | $175,781 |
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
By fiscal year
| Fiscal year | LCAs | Median salary |
|---|---|---|
| FY2023 | 10 | $148,718 |
| FY2024 | 21 | $159,650 |
| FY2025 | 23 | $164,800 |
| FY2026 | 13 | $169,033 |
Cities
- Princeton, NJ31
- Lawrenceville, NJ7
- Madison, NJ5
- Foster City, CA3
- Warren, NJ3
- Berkeley Heights, NJ2
- Basking Ridge, NJ2
- Gainesville, FL2
- Watchung, NJ1
- Walnut, CA1
- Hoboken, NJ1
- Richmond, VA1
- Tarrytown, NY1
- Germantown, TN1
- Germantown, MD1
- Plainsboro, NJ1
- Redwood City, CA1
- Norristown, PA1
- Leander, TX1
- West Allis, WI1
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).